Shikoku, Japan:
Obesity gets worse if white adipose tissue increases while brown adipose tissue decreases. The anti-obesity pyridoacridine alkaloid, kuanoniamine C, was called in to rescue mice from insulin-, IBMX-, and dexamethasone-induced adipogenesis:
https://t.co/pfHZZrs1hY
Society's obsession with narrow-spectrum antivirals called, 3CL protease inhibitors, continues. They all:
*Will end up being swallowed on Day 5, not Day 1 as they need to be
*Lose efficacy with viral evolution
*Can't be used against the flu
*Pro-oxidants
https://t.co/vzMxMjqEyH
After Remicade (infliximab) & methotrexate had failed, Actemra (tocilizumab) was called in to rescue a 43-year old lady, both from RA & from drug-induced proteinuria, purpura, & endothelial damage-dominant nephritis with IgA deposition.
Was it too late??
https://t.co/MQNZlUgPdf
9-19-2022: Fukushima, Japan:
After other treatments had failed, Actemra (tocilizumab) was called in to rescue somebody from MCD complicated by AA amyloidosis:
https://t.co/R6UWmcYKEq
https://t.co/2XdCI0D84h
https://t.co/ZHgg68wu7I
https://t.co/yec24hECe1
https://t.co/G4XJss51zJ
3-18-22: Saitama, Japan:
Actemra (tocilizumab) was called in to rescue a 57-year-old lady from encapsulating peritoneal sclerosis (EPS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, & ascites retention; died in 1 year
https://t.co/MuqhVHDiFQ https://t.co/V8tJIOsCNk
3-2-2022: Gunma & Saitama, Japan: Pro-favipiravir study in which the slightly higher dose (Group 2) performed much better than the slightly lower dose (Group 1). Next, try an even higher dose than Group 2 for even better results:
https://t.co/6gcwXwdrwy
https://t.co/uskOzxSpWM
10-26-2021: New study from Japan: although other antivirals can be used in animals for deadly avian influenza, only the safest can be used in humans at double the COVID-19 dosages:
https://t.co/cYgpzdADKJ
https://t.co/uPez4RJp46
https://t.co/iqA0KJuxCs
https://t.co/iBSYhGZcWT